Back to Results
First PageMeta Content



Safety and early evidence of activity of a first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with selected solid tumors A.
Add to Reading List

Document Date: 2014-11-19 14:29:45


Open Document

File Size: 1,17 MB

Share Result on Facebook